 | • レポートコード：MRC2-11QY04517 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、94ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料はリウマチ性腫瘍随伴症候群治療のグローバル市場について調査・分析したレポートです。種類別（投薬、理学療法、その他）市場規模、用途別（病院、診療所、外来外科センター、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別リウマチ性腫瘍随伴症候群治療の競争状況、市場シェア ・世界のリウマチ性腫瘍随伴症候群治療市場：種類別市場規模 2015年-2020年（投薬、理学療法、その他） ・世界のリウマチ性腫瘍随伴症候群治療市場：種類別市場規模予測 2021年-2026年（投薬、理学療法、その他） ・世界のリウマチ性腫瘍随伴症候群治療市場：用途別市場規模 2015年-2020年（病院、診療所、外来外科センター、その他） ・世界のリウマチ性腫瘍随伴症候群治療市場：用途別市場規模予測 2021年-2026年（病院、診療所、外来外科センター、その他） ・北米のリウマチ性腫瘍随伴症候群治療市場分析：米国、カナダ ・ヨーロッパのリウマチ性腫瘍随伴症候群治療市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアのリウマチ性腫瘍随伴症候群治療市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米のリウマチ性腫瘍随伴症候群治療市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカのリウマチ性腫瘍随伴症候群治療市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Siemens Healthineers、Koninklijke Philips、General Electric、Esaote、NeuroLogica、Masimo、York Instruments、Neusoft Medical Systems、Canon Medical Systems ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
A paraneoplastic syndrome is a rare group of disorder that is triggered by an abnormal immune system response caused by the neoplasm. This syndrome mostly occurs when cancer-fighting antibodies mistakenly attack normal cells in the nervous system. The prevalence of this disorder can be typically seen in the middle-aged population to older population. This syndrome mostly occurs with patients suffering from lung, ovarian, or breast cancers.
Market Analysis and Insights: Global Rheumatologic Paraneoplastic Syndrome Treatment Market
The global Rheumatologic Paraneoplastic Syndrome Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Rheumatologic Paraneoplastic Syndrome Treatment Scope and Market Size
Rheumatologic Paraneoplastic Syndrome Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Rheumatologic Paraneoplastic Syndrome Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Siemens Healthineers
Koninklijke Philips
General Electric
Esaote
NeuroLogica
Masimo
York Instruments
Neusoft Medical Systems
Canon Medical Systems
Market segment by Type, the product can be split into
Medication
Physical Therapy
Others
Market segment by Application, split into
Hospitals
Clinics
Ambulatory Surgical Centers
Others
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Rheumatologic Paraneoplastic Syndrome Treatment Revenue
1.4 Market by Type
1.4.1 Global Rheumatologic Paraneoplastic Syndrome Treatment Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Medication
1.4.3 Physical Therapy
1.4.4 Others
1.5 Market by Application
1.5.1 Global Rheumatologic Paraneoplastic Syndrome Treatment Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Ambulatory Surgical Centers
1.5.5 Others
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Rheumatologic Paraneoplastic Syndrome Treatment Market Perspective (2015-2026)
2.2 Global Rheumatologic Paraneoplastic Syndrome Treatment Growth Trends by Regions
2.2.1 Rheumatologic Paraneoplastic Syndrome Treatment Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Rheumatologic Paraneoplastic Syndrome Treatment Historic Market Share by Regions (2015-2020)
2.2.3 Rheumatologic Paraneoplastic Syndrome Treatment Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Rheumatologic Paraneoplastic Syndrome Treatment Market Growth Strategy
2.3.6 Primary Interviews with Key Rheumatologic Paraneoplastic Syndrome Treatment Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Rheumatologic Paraneoplastic Syndrome Treatment Players by Market Size
3.1.1 Global Top Rheumatologic Paraneoplastic Syndrome Treatment Players by Revenue (2015-2020)
3.1.2 Global Rheumatologic Paraneoplastic Syndrome Treatment Revenue Market Share by Players (2015-2020)
3.1.3 Global Rheumatologic Paraneoplastic Syndrome Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Rheumatologic Paraneoplastic Syndrome Treatment Market Concentration Ratio
3.2.1 Global Rheumatologic Paraneoplastic Syndrome Treatment Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Rheumatologic Paraneoplastic Syndrome Treatment Revenue in 2019
3.3 Rheumatologic Paraneoplastic Syndrome Treatment Key Players Head office and Area Served
3.4 Key Players Rheumatologic Paraneoplastic Syndrome Treatment Product Solution and Service
3.5 Date of Enter into Rheumatologic Paraneoplastic Syndrome Treatment Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Rheumatologic Paraneoplastic Syndrome Treatment Historic Market Size by Type (2015-2020)
4.2 Global Rheumatologic Paraneoplastic Syndrome Treatment Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Rheumatologic Paraneoplastic Syndrome Treatment Market Size by Application (2015-2020)
5.2 Global Rheumatologic Paraneoplastic Syndrome Treatment Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Rheumatologic Paraneoplastic Syndrome Treatment Market Size (2015-2020)
6.2 Rheumatologic Paraneoplastic Syndrome Treatment Key Players in North America (2019-2020)
6.3 North America Rheumatologic Paraneoplastic Syndrome Treatment Market Size by Type (2015-2020)
6.4 North America Rheumatologic Paraneoplastic Syndrome Treatment Market Size by Application (2015-2020)
7 Europe
7.1 Europe Rheumatologic Paraneoplastic Syndrome Treatment Market Size (2015-2020)
7.2 Rheumatologic Paraneoplastic Syndrome Treatment Key Players in Europe (2019-2020)
7.3 Europe Rheumatologic Paraneoplastic Syndrome Treatment Market Size by Type (2015-2020)
7.4 Europe Rheumatologic Paraneoplastic Syndrome Treatment Market Size by Application (2015-2020)
8 China
8.1 China Rheumatologic Paraneoplastic Syndrome Treatment Market Size (2015-2020)
8.2 Rheumatologic Paraneoplastic Syndrome Treatment Key Players in China (2019-2020)
8.3 China Rheumatologic Paraneoplastic Syndrome Treatment Market Size by Type (2015-2020)
8.4 China Rheumatologic Paraneoplastic Syndrome Treatment Market Size by Application (2015-2020)
9 Japan
9.1 Japan Rheumatologic Paraneoplastic Syndrome Treatment Market Size (2015-2020)
9.2 Rheumatologic Paraneoplastic Syndrome Treatment Key Players in Japan (2019-2020)
9.3 Japan Rheumatologic Paraneoplastic Syndrome Treatment Market Size by Type (2015-2020)
9.4 Japan Rheumatologic Paraneoplastic Syndrome Treatment Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Rheumatologic Paraneoplastic Syndrome Treatment Market Size (2015-2020)
10.2 Rheumatologic Paraneoplastic Syndrome Treatment Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Rheumatologic Paraneoplastic Syndrome Treatment Market Size by Type (2015-2020)
10.4 Southeast Asia Rheumatologic Paraneoplastic Syndrome Treatment Market Size by Application (2015-2020)
11 India
11.1 India Rheumatologic Paraneoplastic Syndrome Treatment Market Size (2015-2020)
11.2 Rheumatologic Paraneoplastic Syndrome Treatment Key Players in India (2019-2020)
11.3 India Rheumatologic Paraneoplastic Syndrome Treatment Market Size by Type (2015-2020)
11.4 India Rheumatologic Paraneoplastic Syndrome Treatment Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Rheumatologic Paraneoplastic Syndrome Treatment Market Size (2015-2020)
12.2 Rheumatologic Paraneoplastic Syndrome Treatment Key Players in Central & South America (2019-2020)
12.3 Central & South America Rheumatologic Paraneoplastic Syndrome Treatment Market Size by Type (2015-2020)
12.4 Central & South America Rheumatologic Paraneoplastic Syndrome Treatment Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Siemens Healthineers
13.1.1 Siemens Healthineers Company Details
13.1.2 Siemens Healthineers Business Overview
13.1.3 Siemens Healthineers Rheumatologic Paraneoplastic Syndrome Treatment Introduction
13.1.4 Siemens Healthineers Revenue in Rheumatologic Paraneoplastic Syndrome Treatment Business (2015-2020))
13.1.5 Siemens Healthineers Recent Development
13.2 Koninklijke Philips
13.2.1 Koninklijke Philips Company Details
13.2.2 Koninklijke Philips Business Overview
13.2.3 Koninklijke Philips Rheumatologic Paraneoplastic Syndrome Treatment Introduction
13.2.4 Koninklijke Philips Revenue in Rheumatologic Paraneoplastic Syndrome Treatment Business (2015-2020)
13.2.5 Koninklijke Philips Recent Development
13.3 General Electric
13.3.1 General Electric Company Details
13.3.2 General Electric Business Overview
13.3.3 General Electric Rheumatologic Paraneoplastic Syndrome Treatment Introduction
13.3.4 General Electric Revenue in Rheumatologic Paraneoplastic Syndrome Treatment Business (2015-2020)
13.3.5 General Electric Recent Development
13.4 Esaote
13.4.1 Esaote Company Details
13.4.2 Esaote Business Overview
13.4.3 Esaote Rheumatologic Paraneoplastic Syndrome Treatment Introduction
13.4.4 Esaote Revenue in Rheumatologic Paraneoplastic Syndrome Treatment Business (2015-2020)
13.4.5 Esaote Recent Development
13.5 NeuroLogica
13.5.1 NeuroLogica Company Details
13.5.2 NeuroLogica Business Overview
13.5.3 NeuroLogica Rheumatologic Paraneoplastic Syndrome Treatment Introduction
13.5.4 NeuroLogica Revenue in Rheumatologic Paraneoplastic Syndrome Treatment Business (2015-2020)
13.5.5 NeuroLogica Recent Development
13.6 Masimo
13.6.1 Masimo Company Details
13.6.2 Masimo Business Overview
13.6.3 Masimo Rheumatologic Paraneoplastic Syndrome Treatment Introduction
13.6.4 Masimo Revenue in Rheumatologic Paraneoplastic Syndrome Treatment Business (2015-2020)
13.6.5 Masimo Recent Development
13.7 York Instruments
13.7.1 York Instruments Company Details
13.7.2 York Instruments Business Overview
13.7.3 York Instruments Rheumatologic Paraneoplastic Syndrome Treatment Introduction
13.7.4 York Instruments Revenue in Rheumatologic Paraneoplastic Syndrome Treatment Business (2015-2020)
13.7.5 York Instruments Recent Development
13.8 Neusoft Medical Systems
13.8.1 Neusoft Medical Systems Company Details
13.8.2 Neusoft Medical Systems Business Overview
13.8.3 Neusoft Medical Systems Rheumatologic Paraneoplastic Syndrome Treatment Introduction
13.8.4 Neusoft Medical Systems Revenue in Rheumatologic Paraneoplastic Syndrome Treatment Business (2015-2020)
13.8.5 Neusoft Medical Systems Recent Development
13.9 Canon Medical Systems
13.9.1 Canon Medical Systems Company Details
13.9.2 Canon Medical Systems Business Overview
13.9.3 Canon Medical Systems Rheumatologic Paraneoplastic Syndrome Treatment Introduction
13.9.4 Canon Medical Systems Revenue in Rheumatologic Paraneoplastic Syndrome Treatment Business (2015-2020)
13.9.5 Canon Medical Systems Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Rheumatologic Paraneoplastic Syndrome Treatment Key Market Segments
Table 2. Key Players Covered: Ranking by Rheumatologic Paraneoplastic Syndrome Treatment Revenue
Table 3. Ranking of Global Top Rheumatologic Paraneoplastic Syndrome Treatment Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Rheumatologic Paraneoplastic Syndrome Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Medication
Table 6. Key Players of Physical Therapy
Table 7. Key Players of Others
Table 8. Global Rheumatologic Paraneoplastic Syndrome Treatment Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 9. Global Rheumatologic Paraneoplastic Syndrome Treatment Market Size by Regions (US$ Million): 2020 VS 2026
Table 10. Global Rheumatologic Paraneoplastic Syndrome Treatment Market Size by Regions (2015-2020) (US$ Million)
Table 11. Global Rheumatologic Paraneoplastic Syndrome Treatment Market Share by Regions (2015-2020)
Table 12. Global Rheumatologic Paraneoplastic Syndrome Treatment Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 13. Global Rheumatologic Paraneoplastic Syndrome Treatment Market Share by Regions (2021-2026)
Table 14. Market Top Trends
Table 15. Key Drivers: Impact Analysis
Table 16. Key Challenges
Table 17. Rheumatologic Paraneoplastic Syndrome Treatment Market Growth Strategy
Table 18. Main Points Interviewed from Key Rheumatologic Paraneoplastic Syndrome Treatment Players
Table 19. Global Rheumatologic Paraneoplastic Syndrome Treatment Revenue by Players (2015-2020) (Million US$)
Table 20. Global Rheumatologic Paraneoplastic Syndrome Treatment Market Share by Players (2015-2020)
Table 21. Global Top Rheumatologic Paraneoplastic Syndrome Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Rheumatologic Paraneoplastic Syndrome Treatment as of 2019)
Table 22. Global Rheumatologic Paraneoplastic Syndrome Treatment by Players Market Concentration Ratio (CR5 and HHI)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Rheumatologic Paraneoplastic Syndrome Treatment Product Solution and Service
Table 25. Date of Enter into Rheumatologic Paraneoplastic Syndrome Treatment Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Rheumatologic Paraneoplastic Syndrome Treatment Market Size by Type (2015-2020) (Million US$)
Table 28. Global Rheumatologic Paraneoplastic Syndrome Treatment Market Size Share by Type (2015-2020)
Table 29. Global Rheumatologic Paraneoplastic Syndrome Treatment Revenue Market Share by Type (2021-2026)
Table 30. Global Rheumatologic Paraneoplastic Syndrome Treatment Market Size Share by Application (2015-2020)
Table 31. Global Rheumatologic Paraneoplastic Syndrome Treatment Market Size by Application (2015-2020) (Million US$)
Table 32. Global Rheumatologic Paraneoplastic Syndrome Treatment Market Size Share by Application (2021-2026)
Table 33. North America Key Players Rheumatologic Paraneoplastic Syndrome Treatment Revenue (2019-2020) (Million US$)
Table 34. North America Key Players Rheumatologic Paraneoplastic Syndrome Treatment Market Share (2019-2020)
Table 35. North America Rheumatologic Paraneoplastic Syndrome Treatment Market Size by Type (2015-2020) (Million US$)
Table 36. North America Rheumatologic Paraneoplastic Syndrome Treatment Market Share by Type (2015-2020)
Table 37. North America Rheumatologic Paraneoplastic Syndrome Treatment Market Size by Application (2015-2020) (Million US$)
Table 38. North America Rheumatologic Paraneoplastic Syndrome Treatment Market Share by Application (2015-2020)
Table 39. Europe Key Players Rheumatologic Paraneoplastic Syndrome Treatment Revenue (2019-2020) (Million US$)
Table 40. Europe Key Players Rheumatologic Paraneoplastic Syndrome Treatment Market Share (2019-2020)
Table 41. Europe Rheumatologic Paraneoplastic Syndrome Treatment Market Size by Type (2015-2020) (Million US$)
Table 42. Europe Rheumatologic Paraneoplastic Syndrome Treatment Market Share by Type (2015-2020)
Table 43. Europe Rheumatologic Paraneoplastic Syndrome Treatment Market Size by Application (2015-2020) (Million US$)
Table 44. Europe Rheumatologic Paraneoplastic Syndrome Treatment Market Share by Application (2015-2020)
Table 45. China Key Players Rheumatologic Paraneoplastic Syndrome Treatment Revenue (2019-2020) (Million US$)
Table 46. China Key Players Rheumatologic Paraneoplastic Syndrome Treatment Market Share (2019-2020)
Table 47. China Rheumatologic Paraneoplastic Syndrome Treatment Market Size by Type (2015-2020) (Million US$)
Table 48. China Rheumatologic Paraneoplastic Syndrome Treatment Market Share by Type (2015-2020)
Table 49. China Rheumatologic Paraneoplastic Syndrome Treatment Market Size by Application (2015-2020) (Million US$)
Table 50. China Rheumatologic Paraneoplastic Syndrome Treatment Market Share by Application (2015-2020)
Table 51. Japan Key Players Rheumatologic Paraneoplastic Syndrome Treatment Revenue (2019-2020) (Million US$)
Table 52. Japan Key Players Rheumatologic Paraneoplastic Syndrome Treatment Market Share (2019-2020)
Table 53. Japan Rheumatologic Paraneoplastic Syndrome Treatment Market Size by Type (2015-2020) (Million US$)
Table 54. Japan Rheumatologic Paraneoplastic Syndrome Treatment Market Share by Type (2015-2020)
Table 55. Japan Rheumatologic Paraneoplastic Syndrome Treatment Market Size by Application (2015-2020) (Million US$)
Table 56. Japan Rheumatologic Paraneoplastic Syndrome Treatment Market Share by Application (2015-2020)
Table 57. Southeast Asia Key Players Rheumatologic Paraneoplastic Syndrome Treatment Revenue (2019-2020) (Million US$)
Table 58. Southeast Asia Key Players Rheumatologic Paraneoplastic Syndrome Treatment Market Share (2019-2020)
Table 59. Southeast Asia Rheumatologic Paraneoplastic Syndrome Treatment Market Size by Type (2015-2020) (Million US$)
Table 60. Southeast Asia Rheumatologic Paraneoplastic Syndrome Treatment Market Share by Type (2015-2020)
Table 61. Southeast Asia Rheumatologic Paraneoplastic Syndrome Treatment Market Size by Application (2015-2020) (Million US$)
Table 62. Southeast Asia Rheumatologic Paraneoplastic Syndrome Treatment Market Share by Application (2015-2020)
Table 63. India Key Players Rheumatologic Paraneoplastic Syndrome Treatment Revenue (2019-2020) (Million US$)
Table 64. India Key Players Rheumatologic Paraneoplastic Syndrome Treatment Market Share (2019-2020)
Table 65. India Rheumatologic Paraneoplastic Syndrome Treatment Market Size by Type (2015-2020) (Million US$)
Table 66. India Rheumatologic Paraneoplastic Syndrome Treatment Market Share by Type (2015-2020)
Table 67. India Rheumatologic Paraneoplastic Syndrome Treatment Market Size by Application (2015-2020) (Million US$)
Table 68. India Rheumatologic Paraneoplastic Syndrome Treatment Market Share by Application (2015-2020)
Table 69. Central & South America Key Players Rheumatologic Paraneoplastic Syndrome Treatment Revenue (2019-2020) (Million US$)
Table 70. Central & South America Key Players Rheumatologic Paraneoplastic Syndrome Treatment Market Share (2019-2020)
Table 71. Central & South America Rheumatologic Paraneoplastic Syndrome Treatment Market Size by Type (2015-2020) (Million US$)
Table 72. Central & South America Rheumatologic Paraneoplastic Syndrome Treatment Market Share by Type (2015-2020)
Table 73. Central & South America Rheumatologic Paraneoplastic Syndrome Treatment Market Size by Application (2015-2020) (Million US$)
Table 74. Central & South America Rheumatologic Paraneoplastic Syndrome Treatment Market Share by Application (2015-2020)
Table 75. Siemens Healthineers Company Details
Table 76. Siemens Healthineers Business Overview
Table 77. Siemens Healthineers Product
Table 78. Siemens Healthineers Revenue in Rheumatologic Paraneoplastic Syndrome Treatment Business (2015-2020) (Million US$)
Table 79. Siemens Healthineers Recent Development
Table 80. Koninklijke Philips Company Details
Table 81. Koninklijke Philips Business Overview
Table 82. Koninklijke Philips Product
Table 83. Koninklijke Philips Revenue in Rheumatologic Paraneoplastic Syndrome Treatment Business (2015-2020) (Million US$)
Table 84. Koninklijke Philips Recent Development
Table 85. General Electric Company Details
Table 86. General Electric Business Overview
Table 87. General Electric Product
Table 88. General Electric Revenue in Rheumatologic Paraneoplastic Syndrome Treatment Business (2015-2020) (Million US$)
Table 89. General Electric Recent Development
Table 90. Esaote Company Details
Table 91. Esaote Business Overview
Table 92. Esaote Product
Table 93. Esaote Revenue in Rheumatologic Paraneoplastic Syndrome Treatment Business (2015-2020) (Million US$)
Table 94. Esaote Recent Development
Table 95. NeuroLogica Company Details
Table 96. NeuroLogica Business Overview
Table 97. NeuroLogica Product
Table 98. NeuroLogica Revenue in Rheumatologic Paraneoplastic Syndrome Treatment Business (2015-2020) (Million US$)
Table 99. NeuroLogica Recent Development
Table 100. Masimo Company Details
Table 101. Masimo Business Overview
Table 102. Masimo Product
Table 103. Masimo Revenue in Rheumatologic Paraneoplastic Syndrome Treatment Business (2015-2020) (Million US$)
Table 104. Masimo Recent Development
Table 105. York Instruments Company Details
Table 106. York Instruments Business Overview
Table 107. York Instruments Product
Table 108. York Instruments Revenue in Rheumatologic Paraneoplastic Syndrome Treatment Business (2015-2020) (Million US$)
Table 109. York Instruments Recent Development
Table 110. Neusoft Medical Systems Business Overview
Table 111. Neusoft Medical Systems Product
Table 112. Neusoft Medical Systems Company Details
Table 113. Neusoft Medical Systems Revenue in Rheumatologic Paraneoplastic Syndrome Treatment Business (2015-2020) (Million US$)
Table 114. Neusoft Medical Systems Recent Development
Table 115. Canon Medical Systems Company Details
Table 116. Canon Medical Systems Business Overview
Table 117. Canon Medical Systems Product
Table 118. Canon Medical Systems Revenue in Rheumatologic Paraneoplastic Syndrome Treatment Business (2015-2020) (Million US$)
Table 119. Canon Medical Systems Recent Development
Table 120. Research Programs/Design for This Report
Table 121. Key Data Information from Secondary Sources
Table 122. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Rheumatologic Paraneoplastic Syndrome Treatment Market Share by Type: 2020 VS 2026
Figure 2. Medication Features
Figure 3. Physical Therapy Features
Figure 4. Others Features
Figure 5. Global Rheumatologic Paraneoplastic Syndrome Treatment Market Share by Application: 2020 VS 2026
Figure 6. Hospitals Case Studies
Figure 7. Clinics Case Studies
Figure 8. Ambulatory Surgical Centers Case Studies
Figure 9. Others Case Studies
Figure 10. Rheumatologic Paraneoplastic Syndrome Treatment Report Years Considered
Figure 11. Global Rheumatologic Paraneoplastic Syndrome Treatment Market Size YoY Growth 2015-2026 (US$ Million)
Figure 12. Global Rheumatologic Paraneoplastic Syndrome Treatment Market Share by Regions: 2020 VS 2026
Figure 13. Global Rheumatologic Paraneoplastic Syndrome Treatment Market Share by Regions (2021-2026)
Figure 14. Porter's Five Forces Analysis
Figure 15. Global Rheumatologic Paraneoplastic Syndrome Treatment Market Share by Players in 2019
Figure 16. Global Top Rheumatologic Paraneoplastic Syndrome Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Rheumatologic Paraneoplastic Syndrome Treatment as of 2019
Figure 17. The Top 10 and 5 Players Market Share by Rheumatologic Paraneoplastic Syndrome Treatment Revenue in 2019
Figure 18. North America Rheumatologic Paraneoplastic Syndrome Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Europe Rheumatologic Paraneoplastic Syndrome Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. China Rheumatologic Paraneoplastic Syndrome Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Japan Rheumatologic Paraneoplastic Syndrome Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Southeast Asia Rheumatologic Paraneoplastic Syndrome Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. India Rheumatologic Paraneoplastic Syndrome Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Central & South America Rheumatologic Paraneoplastic Syndrome Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Bottom-up and Top-down Approaches for This Report
Figure 26. Data Triangulation
Figure 27. Key Executives Interviewed
腫瘍随伴症候群治療の世界市場（～2026年） A paraneoplastic syndrome is a rare group of disorder that is triggered by an abnormal immune system response caused by the neoplasm. This syndrome mostly occurs when cancer-fighting antibodies mistakenly attack normal cells in the nervous system. The prevalence of this disorder can be typically see…- 神経学的腫瘍随伴症候群治療の世界市場（～2026年） A paraneoplastic syndrome is a rare group of disorder that is triggered by an abnormal immune system response caused by the neoplasm. This syndrome mostly occurs when cancer-fighting antibodies mistakenly attack normal cells in the nervous system. The prevalence of this disorder can be typically see…
- アスペルガー症候群治療の世界市場（～2026年） The Asperger syndrome is a type of developmental disorders known as Autistic Spectrum Disorder (ASD). These disorders initiate in childhood and stay with individuals until their adult life. Children with the Asperger syndrome function better than those with autism, and they have normal intelligence …
- 胸郭出口症候群治療の世界市場（～2026年） Thoracic outlet syndrome is a group of heterogeneous and disabling upper-extremity disorders that occur due to extrinsic compression of neurovascular structures between the clavicle and the first rib. There are three distinct types of thoracic outlet syndrome viz. neurogenic thoracic outlet syndrome…
- ウォルフパーキンソンホワイト症候群治療の世界市場（～2026年） Wolff-Parkinson-White (WPW) syndrome is a rare congenital heart disorder involving irregularities in the electrical transmission system of the heart. In WPW syndrome, an abnormal alternate electrical pathway exists resulting in arrhythmias (abnormal heartbeat rhythms) and tachycardia (faster than no…